Literature DB >> 20962285

Allergic contact dermatitis: a case series and review for the ophthalmologist.

Sharon Morris1, Richard Barlow, Dinesh Selva, Raman Malhotra.   

Abstract

Eyelid dermatitis is most commonly caused by an allergenic response, potentially from exposure at another site, rather than from local toxicity. Yet allergic contact dermatitis is a diagnosis often missed by ophthalmologists. The authors review the literature and detail their experience relating to the causes, clinical features and management of this condition. 14 patients over a 2-year period that were referred to the oculoplastic service for a further opinion were reviewed in a retrospective, non-comparative study. All patients underwent patch testing for diagnosis. 8 of the 14 patients had delays of more than 6 months from symptoms to diagnosis. In six of these, this was greater than 1 year. Similar delays are reported in the literature. 79% of the cases were referred by ophthalmologists. Although two of the patients were biopsied, this did not help in making the diagnosis. 13 patients had disease restricted to the eyelids, though only five of these had direct contact of the allergen with the eyelids. Two patients were also sensitised to topical steroid creams prescribed for their treatment. All patients improved after removal of the allergen. Further clinical features and management options from the literature are reviewed and discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20962285     DOI: 10.1136/bjo.2009.174607

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

1.  Seven Common Allergen Groups Causing Eyelid Dermatitis: Education and Avoidance Strategies.

Authors:  Crystal X Huang; James A Yiannias; Jill M Killian; Joanne F Shen
Journal:  Clin Ophthalmol       Date:  2021-04-12

2.  Allergic Contact Dermatitis to Eye Drops.

Authors:  Yasmeen Jabeen Bhat; Sumaya Zeerak; Iffat Hassan
Journal:  Indian J Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.